Skip to content
Clinical Trials – home

Rare diseases

Investigational molecules

Locations

Our offerNewsroom

Not recruiting

Study on the Effects and Safety of Namilumab for Patients with Chronic Lung Sarcoidosis

Verified siteInvestigational
Clinical Trials Concierge

Prefer not to search? Our Concierge searches the trials for you.

What is this trial about?

A plain-language summary of the goals, design and what participants do

This clinical trial is focused on studying a lung condition called chronic pulmonary sarcoidosis. This disease involves inflammation in the lungs, which can cause breathing difficulties and other health issues. The study is testing a treatment called Namilumab, which is a type of medication known as a monoclonal antibody. Monoclonal antibodies are proteins designed to target specific parts of the immune system to help reduce inflammation.

The purpose of the study is to evaluate how effective Namilumab is in reducing the need for additional treatments when the symptoms of sarcoidosis worsen. Participants in the study will receive either Namilumab or a placebo, which is a substance with no active medication. The study will follow participants over a period of time to monitor their response to the treatment and any changes in their condition.

Throughout the study, participants will receive regular check-ups to assess their lung function and overall health. This will include physical examinations, vital sign measurements, and other routine tests to ensure safety and track the effectiveness of the treatment. The study aims to provide valuable information on whether Namilumab can be a beneficial treatment option for those living with chronic pulmonary sarcoidosis.

The research process

The trial runs in 5 steps – from screening to follow-up. Each step says what happens and what the team monitors.

  1. Step 1

    Joining the study

    Upon joining the study, the participant will be randomly assigned to receive either the namilumab treatment or a placebo. This process is double-blind, meaning neither the participant nor the researchers will know which treatment is being administered.

    The participant must meet specific criteria, such as being 18 years or older, having a documented history of sarcoidosis for at least six months, and having completed the primary series of COVID-19 vaccinations at least two weeks prior to randomization.

  2. Step 2

    Treatment administration

    The treatment involves a subcutaneous injection of either namilumab or a placebo. The exact dosage and frequency of administration will be determined by the study protocol.

    Participants will receive these injections over a specified period, with regular monitoring to assess the treatment's effects.

  3. Step 3

    Monitoring and assessment

    Throughout the study, participants will undergo various assessments to monitor their health and the treatment's impact. This includes physical examinations, vital signs checks, electrocardiograms (ECGs), and laboratory tests.

    The primary goal is to evaluate the effect of namilumab on the need for additional treatment due to worsening sarcoidosis.

  4. Step 4

    Evaluation of outcomes

    The study will measure several outcomes, such as the proportion of participants needing additional treatment during the double-blind period and changes in lung function and quality of life scores.

    Safety and tolerability of the treatment will also be assessed, with attention to any adverse effects experienced by participants.

  5. Step 5

    Open-label extension

    After the initial double-blind phase, participants may enter an open-label extension where all will receive namilumab. This phase allows further evaluation of the treatment's long-term effects.

    Participants will continue to be monitored closely to ensure their safety and to gather additional data on the treatment's efficacy.

Who can join the trial?

10 criteria

  • Must be a male or female who is **18 years or older**.
  • Must be able and willing to provide **written informed consent**. This means you agree to follow the study rules and understand what the study involves.
  • Must have a history of **sarcoidosis** for **6 months or more**, with proof in your medical records.
  • Must show signs of **sarcoidosis** through:
    • A **HRCT** scan that matches **Pulmonary Sarcoidosis**.
    • A score of **2 or more** on the **Medical Research Council Dyspnea scale**, which measures breathing difficulty.
    • One or more of the following:
      • A **FDG-PET** scan showing signs of **pulmonary sarcoidosis** with a **SUVmax** of **3 or more**.
      • Recent worsening of **sarcoidosis** symptoms.
      • Recent increase in lung problems when reducing **oral corticosteroids (OCS)** or **immunosuppressive therapies (ISTs)**.
      • Must have a **Body Mass Index (BMI)** of **40 kg/m² or less** at the time of screening. **BMI** is a measure of body fat based on height and weight.
      • Must have completed the primary series of **COVID-19 vaccinations** at least **2 weeks** before starting the study.

Who cannot join the trial?

10 criteria

  • Patients who have other serious health conditions that could interfere with the study.
  • Patients who are currently taking medications that might affect the study results.
  • Patients who have had a recent surgery or medical procedure.
  • Patients who are pregnant or breastfeeding.
  • Patients who have a history of allergic reactions to similar treatments.
  • Patients who are unable to follow the study procedures or attend study visits.
  • Patients who have participated in another clinical trial recently.
  • Patients who have a history of substance abuse or alcohol dependency.
  • Patients who have an active infection or illness that requires treatment.
  • Patients who have been diagnosed with a mental health condition that might affect their ability to participate.
Clinical Trials Concierge

Prefer not to search? Our Concierge searches the trials for you.

Tell us about your condition – we search every trial in Europe and connect you with the right site.

We usually reply within a few days

Verified sites

All sites with verified contact details – recruitment status may not be available; ask directly

Trial locations

Where you can join this trial

Countries are shaded by recruitment status. Click a recruiting country to ask about joining there.

Not recruiting
Not finding your country?

Not sure what to do next?

Joining a clinical trial can seem overwhelming. We guide you step by step, so you know exactly what to expect and how we support you through the process.

See the full process and FAQ

Investigated drugs

Namilumab is a medication being studied for its potential to help people with chronic pulmonary sarcoidosis. This condition affects the lungs, and the study aims to see if namilumab can reduce the need for additional treatments when the disease gets worse.

What is already known about the treatment

Namilumab – Namilumab is administered as an injection, typically given under the skin. It is currently being studied in clinical trials for its potential use in treating chronic pulmonary sarcoidosis, a condition characterized by inflammation in the lungs. The medication works by targeting and inhibiting a specific protein involved in the inflammatory process, thereby reducing inflammation. Namilumab is classified as a monoclonal antibody, a type of medication designed to specifically target certain molecules in the body.

Investigated diseases

Chronic Pulmonary Sarcoidosis – This is a condition characterized by the growth of tiny collections of inflammatory cells in the lungs. These clusters, known as granulomas, can affect how the lungs function. Over time, the granulomas may lead to scarring and stiffness in the lung tissue, which can make breathing difficult. The disease can progress slowly, with symptoms that may include a persistent cough, shortness of breath, and chest pain. The exact cause of sarcoidosis is unknown, but it is believed to involve an abnormal immune response. The condition can vary greatly in severity and may remain stable or worsen over time.
Trial detailsLast updated 7 Oct 2026
Age18+ yearsPhasePhase IITrial ID2024-511115-25-00Protocol codeKIN-1902-2001Estimated enrolment100 patientsSponsorKinevant Sciences GmbH

sourced from the EU Clinical Trials Register and site verification

Want to learn more about this trial or check if you can participate?

Clinical Trials Concierge

Prefer not to search? Our Concierge searches the trials for you.

Tell us about your condition – we search every trial in Europe and connect you with the right site.